Lipicure CV 20mg/75mg Capsule is a combination pharmaceutical formulation containing Atorvastatin 20mg and Clopidogrel 75mg, indicated for the management of cardiovascular diseases. Atorvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), thereby reducing the risk of atherosclerosis and associated cardiovascular events. Clopidogrel, an antiplatelet agent, inhibits adenosine diphosphate (ADP)-induced platelet aggregation by irreversibly binding to the P2Y12 receptor on platelets, preventing thrombus formation. This combination is particularly beneficial in patients with a history of acute coronary syndrome, recent myocardial infarction, stroke, or peripheral arterial disease, where both lipid control and platelet inhibition are critical to prevent recurrent ischemic events. Lipicure CV should be administered under medical supervision, considering potential drug interactions and contraindications such as active bleeding or hypersensitivity to components. Regular monitoring of lipid profiles, liver function tests, and hematological parameters is recommended during therapy. Adverse effects may include gastrointestinal disturbances, myalgia, bleeding tendencies, and rare but serious events like hepatotoxicity or thrombotic thrombocytopenic purpura. Patient adherence to prescribed dosage and lifestyle modifications enhances therapeutic outcomes.